Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

40%

Ph phase_1

20%

Ph phase_3

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

2(40.0%)

Phase 3Large-scale testing

2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (20.0%)

Phase 22 (40.0%)

Phase 32 (40.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_2

Clinical Trials (5)

Showing 5 of 5 trials

NCT00633659Phase 2

Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia

Completed

NCT00425334Phase 2

Safety Study of Hemospan® in Prostatectomy Patients

Completed

NCT00421200Phase 3

Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

Completed

NCT00494949Phase 1

Increasing Dose Safety Study of Hemospan in Orthopedic Surgery Patients

Completed

NCT00420277Phase 3

Phase III Study of Hemospan® for Treating Hypotension in Hip Arthroplasty

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5